CytomX Therapeutics (CTMX) - Prakiraan wutah bathi kanggo taun ngarep

Tandha merek CytomX Therapeutics Inc (CTMX)

Steady demand for oncology supports CytomX Therapeutics (CTMX), although raw material supply disruptions create risks. The forward net income growth rate reflects expert reactions to macro shifts, where the -26.30 level captures the current state. Cash flow remains unstable and relies on partner payments. Growth prospects are driven by the success of the Probody platform in treating solid tumors and the reduction of drug toxicity.

CTMX - Proyeksi tambahing bathi saben saham ing taun ngarep CytomX Pharma ing rentang 04.07.2022 - 14.11.2026

Rincian metrik lan analitis perusahaan cytomx.com (CTMX)

- rega lan prakiraan konsensus rega:
Bagan rega CytomX Therapeutics Inc|CTMX - Bagan rega target
- indikator kapitalisasi pasar:
Kapitalisasi pasar CytomX Therapeutics|CTMX - Nilai Perusahaan
- indikator kapitalisasi buku:
Nilai Akuntansi saben Saham CytomX Therapeutics|CTMX - Total Aset Bersih|Rasio Kapitalisasi Pasar marang Nilai Buku cytomx.com|CTMX - Nilai Total Aset Perusahaan
- rincian utang lan likuiditas:
Utang marang Ekuitas CytomX Therapeutics|CTMX - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas CytomX Therapeutics, Inc.|CTMX - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku CytomX Therapeutics|CTMX - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan CytomX Therapeutics|Rasio cepet cytomx.com
- statistik bathi lan rasio pasar:
CTMX - Penghasilan resik|Bathi mangsa ngarep CytomX Therapeutics|CTMX - Kapitalisasi marang bathi|Prakiraan rega marang bathi CytomX Therapeutics|CTMX - Rasio nilai perusahaan marang wutah bathi|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan CytomX Therapeutics|CTMX - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan CytomX Therapeutics|CTMX - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan cytomx.com|CTMX - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep CytomX Therapeutics
- informasi babagan volume dodolan lan pendapatan:
CTMX - Pendapatan dodolan perusahaan|Volume dodolan mangsa ngarep perusahaan CytomX Therapeutics Inc|CTMX - Kapitalisasi marang volume dodolan|Multiplikator Forward P/S CytomX Therapeutics
Pambiji fundamental perusahaan:CTMX, CytomX Therapeutics Inc
Barang utama CytomX Therapeutics, Inc.

This indicator measures the expected earnings per share (EPS) dynamics, reflecting the aggregate analyst forecast for future profitability. Growth in this metric signals business expansion, while stagnation indicates a risk of capital stagnation. The current consensus EPS growth forecast for the coming year allows for an assessment of the financial model adaptability of CytomX Therapeutics (CTMX). A positive trend would confirm the commercial efficiency of the Probody platform and the value of strategic partnerships in oncology.

Analisis perusahaan pesaing

Prakiraan wutah bathi resik saben saham kanggo taun ngarep Geron Corp.|Prakiraan wutah bathi resik saben saham kanggo taun ngarep NBTX|Prakiraan wutah bathi kanggo taun ngarep BCYC|Prakiraan wutah bathi kanggo taun ngarep perspectivetherapeutics.com (CATX)|Genelux - Prakiraan wutah bathi saben saham kanggo taun ngarep|Proyeksi tambahing bathi saben saham ing taun ngarep MOLN (molecularpartners.com)|Oncolytics - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep LSTA|moleculin.com (MBRX) - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep Galera Therapeutics, Inc. (GRTX)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Molecular Templates, Inc.